HOOKIPA Pharma Inc.
HOOKDelisted Jul 29, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001760542
HOOKIPA Pharma Inc. was delisted on Jul 29, 2025; its insiders filed their last Form 4 on Oct 9, 2025; 27 institutions reported holding it in 13F filings for Q2 2025, worth $6.01M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by HOOKIPA Pharma Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for HOOKIPA Pharma Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Peters Malte | Chief Executive Officer | 54,347 | Oct 9, 2025 | 1 |
| Coelho Mary Theresa | EVP and CFO | 56,266 | Jul 23, 2025 | 0 |
| Cassidy Sean A | Director | – | Jul 24, 2024 | 0 |
| O'Neill Julie | Director | – | Jun 18, 2024 | 0 |
| van de Winkel Jan | Director | – | Jun 18, 2024 | 0 |
| Kaufman David Ross | Director | – | Jun 18, 2024 | 0 |
| Reilly Timothy P. | Director | – | Jun 18, 2024 | 0 |
| Aldag Jorn | Chief Executive Officer | 71,952 | Apr 17, 2024 | 0 |
| Kandera Reinhard | Chief Financial Officer | 43,092 | Apr 17, 2024 | 0 |
| Orlinger Klaus | Chief Scientific Officer | 10,404 | Apr 17, 2024 | 0 |
| Necina Roman | Chief Operations Officer | 14,876 | Apr 17, 2024 | 0 |
| Winderlich Mark | Chief Development Officer | – | Apr 17, 2024 | 0 |
| Baker Christine D. | Chief Operating Officer | 16,158 | Apr 18, 2023 | 0 |
| Schlienger Katia | Chief Medical Officer | – | Apr 18, 2023 | 0 |
| Matushansky Igor | Chief Medical Officer | 100,240 | Jul 1, 2022 | 0 |
| Kelly Michael Aaron | Director | – | Jul 1, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 2025 (view filing) | Aug 19 | 51 daysLate | Peters MalteChief Executive Officer | SSale | −25.2K | $0.82 | −$20.6K | −31.7%54.3K after | |
| Jul 23, 2025 (view filing) | Jul 22 | 1 day | Peters MalteChief Executive Officer | SSale | −29.2K | $0.92 | −$26.8K | −26.8%79.5K after | |
| Jul 23, 2025 (view filing) | Jul 22 | 1 day | Coelho Mary TheresaEVP and CFO | SSale | −13.6K | $0.92 | −$12.5K | −19.5%56.3K after | |
| Aug 22, 2023 (view filing) | Aug 21 | 1 day | Kandera ReinhardChief Financial Officer | PPurchase | +7.00K | $0.73 | +$5.11K | +19.4%43.1K after | |
| Aug 17, 2023 (view filing) | Aug 16 | 1 day | Kandera ReinhardChief Financial Officer | PPurchase | +8.00K | $0.71 | +$5.68K | +28.5%36.1K after | |
| Jul 11, 2023 (view filing) | Jul 7-11 | 4 days | Aldag JornChief Executive Officer | PPurchase | +10.0K | $0.82 | +$8.20K | +16.1%72.0K after | 2 lots |
| Jul 7, 2023 (view filing) | Jul 5 | 2 days | Aldag JornChief Executive Officer | PPurchase | +5.00K | $0.89 | +$4.45K | +8.8%62.0K after | |
| Jul 5, 2023 (view filing) | Jul 3 | 2 days | Aldag JornChief Executive Officer | PPurchase | +5.00K | $0.89 | +$4.45K | +9.6%57.0K after | |
| Jul 3, 2023 (view filing) | Jun 30 | 3 days | Kandera ReinhardChief Financial Officer | PPurchase | +12.0K | $0.88 | +$10.6K | +74.6%28.1K after | |
| Jan 12, 2022 (view filing)10:07 AM ET | Dec 21, 2021 | 22 daysLate | Matushansky IgorChief Medical Officer | SSale | −14.9K | $2.49 | −$37.2K | −14.9%85.3K after | 3 lots |